Extracorporeal membrane oxygenation (ECMO) is a widely used technique to provide circulatory and/or respiratory support in critically ill patients. ECMO treatment usually necessitates systemic anticoagulation. Unfractionated Heparin (UFH) is a commonly used anticoagulant in patients on ECMO support. In situations where UFH is contraindicated, alternative anticoagulation strategies can be applied, such as the use of direct thrombin inhibitors (DTI). Bivalirudin and argatroban are the most widely used DTIs. In this report we give account of the current evidence regarding dosing, monitoring and complications associated with the use of these agents in ECMO dependent patients.
PaternosterGMaybauerMOSanfilippoF. Heparin anticoagulation for trans-catheter aortic valve implantation on ECMO. In: MaybauerMO (ed.) Extracorporeal membrane oxygenation – an interdisciplinary practice based learning approach. Oxford University Press, in press.
2.
SantonocitoCSanfilippoFMaybauerMO. Bivalirudin for alternative anticoagulation in heparin induced thrombocytopenia during ECMO. In: MaybauerMO (ed.) Extracorporeal membrane oxygenation – an interdisciplinary practice based learning approach. Oxford University Press, in press.
3.
SattlerLABosterJMIvins-O’KeefeKM, et al. Argatroban for anticoagulation in patients requiring venovenous extracorporeal membrane oxygenation in coronavirus disease 2019. Crit Care Explor2021; 3(9): e0530.
4.
BissellBDGabbardTSheridanEA, et al. Evaluation of bivalirudin as the primary anticoagulant in patients receiving extracorporeal membrane oxygenation for SARS-CoV-2-associated acute respiratory failure. Ann Pharmacother2022; 56(4): 387–392.
5.
TrigonisRSmithNPorterS, et al. Efficacy of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO support. J Cardiothorac Vasc Anesth2022; 36(2): 414–418.
6.
SanfilippoFAsmussenSMaybauerDM, et al. Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med2017; 32(5): 312–319.
7.
GeliJCapocciaMMaybauerDM, et al. Argatroban anticoagulation for adult extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med2022; 37(4): 459–471.
8.
CapocciaMGeliJMaybauerMO. Argatroban for anticoagulation in pediatric and adult ECMO. In: MaybauerMO (ed.) Extracorporeal membrane oxygenation – an interdisciplinary practice based learning approach. Oxford University Press, in press.
9.
WalkerEARobertsAJLouieEL, et al. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy. ASAIO J2019; 65(2): 134–138.
10.
ScandroglioAMPieriMNardelliP, et al. Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Artif Organs2021; 45(9): 1097–1103.
11.
SheridanEASekelaMEPandyaKA, et al. Comparison of bivalirudin versus unfractionated heparin for anticoagulation in adult patients on extracorporeal membrane oxygenation. ASAIO J. Epub ahead of print 19October2021. DOI: 10.1097/MAT.0000000000001598.
12.
KaseerHSoto-ArenallMSanghaviD, et al. Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. J Card Surg2020; 35(4): 779–786.
13.
BereiTJLillybladMPWilsonKJ, et al. Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation. ASAIO J2018; 64(5): 623–629.
14.
GiulianoKBigelowBFEtchillEW, et al. Extracorporeal membrane oxygenation complications in heparin- and bivalirudin-treated patients. Crit Care Explor J2021; 3(7): e0485.
15.
RivosecchiRMArakeliansARRyanJ, et al. Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: heparin versus bivalirudin. Crit Care Med2021; 49(7): 1129–1136.
16.
LjajikjEZittermannAMorshuisM, et al. Bivalirudin anticoagulation for left ventricular assist device implantation on an extracorporeal life support system in patients with heparin-induced thrombocytopenia antibodies. Interact Cardiovasc Thorac Surg2017; 25(6): 898–904.
17.
PieriMDonatelliVCalabroMG, et al. Eleven years of venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: from H1N1 to SARS-CoV-2. Experience and Perspectives of a National Referral Center. J Cardiothorac Vasc Anesth. Epub ahead of print 24September2021. DOI: 10.1053/j.jvca.2021.09.029.
18.
HamzahMJardenAMEzetenduC, et al. Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med2020; 21(9): 827–834.
19.
FisserCWinklerMMalfertheinerMV, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care2021; 25(1): 160.
20.
ChoAEJergusonKPetersonJ, et al. Cost-effectiveness of argatroban versus heparin anticoagulation in adult extracorporeal membrane oxygenation patients. Hosp Pharm2021; 56(4): 276–281.
